Effect of vitiligo treatment by compound Glycyrrhizin combined with fractional laser and Triamcinolone Acetonide injection on T Lymphocyte subpopulation

复方甘草酸联合点阵激光和曲安奈德注射治疗白癜风对T淋巴细胞亚群的影响

阅读:1

Abstract

OBJECTIVES: To discuss the effective mechanism of vitiligo treatment by compound glycyrrhizin combined with fractional laser and triamcinolone acetonide injection. METHODS: Forty-two patients with vitiligo vulgaris in the stable phase were classified into combined group (19 cases) and medicine group (23) admitted in dermatology department, Baoding First Central Hospital from January 2017 to July 2018. Both groups took 50mg compound glycyrrhizin orally three times per day, and applied halometasone cream externally once per day. Based on this treatment method, after the combined group adopted fractional laser, triamcinolone acetonide injection encapsulation was used immediately. After the treatment for six months, the curative effect was judged for both groups. Flow cytometry was used to test the changes of T lymphocyte subpopulation in peripheral blood before and after treatment. Meanwhile, immunohistochemical method was adopted to determine CD(4) (+) and CD(8) (+) T lymphocyte expression level. Besides, the normal control group was set up. RESULTS: The efficacy of combined group and medicine group were 73.68% and 56.52% respectively, P<0.05. The comparison of CD(3) (+), CD(4) (+), CD(8) (+) and CD(4) (+)/CD(8) (+) T lymphocyte level in serum and skin damage before and after treatment had no statistical significance (P>0.05). Serum CD(4) (+) T cells of vitiligo patients reduced, compared with the normal control group (P<0.05), and CD(4) (+)/CD(8) (+) declined (P<0.05). CD(4) (+) and CD(8) (+) T lymphocytes at the skin damage of patients increased, compared with normal control group (P<0.05). CONCLUSIONS: Compound glycyrrhizin combined with fractional laser and triamcinolone acetonide injection has good clinical effect in the treatment of vitiligo vulgaris in the stable phase, and its effective mechanism may have nothing to do with T lymphocyte subpopulation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。